From the lab bench to the frontier of AI — I've spent my career at the intersection of science, curiosity, and the belief that the right tools in the right hands can change what's possible for patients.
B.S. Cell & Molecular Biology, UC Santa Cruz — with early hands-on work applying genomic data to improve outcomes in pediatric tumors.
2017 – 2020
Enriching my understanding of the biotech industry
A formative stretch across varying roles — from client services to research — that gave me a wide-angle view of how the industry operates, from discovery to delivery.
2020 – 2025
Developing life-changing medicine for rare disease
In the lab contributing to the science behind antibody-oligonucleotide conjugates (AOCs) — a novel approach to restoring function in patients living with rare muscle disease. Alongside the bench work, I pursued my MBA at USC, building the business fluency to match my scientific foundation.
2025 – today
At the forefront of AI in biotech
Now at a biotech as an AI Product Partner — shaping how artificial intelligence can accelerate drug discovery, streamline R&D, and ultimately get better medicine to patients faster.
In the Lab — Published Research
A chapter of my career spent in the lab, contributing to early-stage research on a platform with the potential to transform treatment for patients with rare muscle disease.
Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for AOCs for Drug Development
Journal of Medicinal Chemistry · 2024 · Cochran, Marks, Albin et al. incl. Olecya Tyaglo · View paper →
AOC 1044 Mediated Exon 44 Skipping and Restoration of Dystrophin in a Mouse Model of Duchenne Muscular Dystrophy
Avidity Biosciences · Karamanlidis, Etxaniz, Missinato et al. incl. Olecya Tyaglo · View paper →
Antibody-Oligonucleotide Conjugates (AOCs) Demonstrate Potent and Durable Exon Skipping and Dystrophin Restoration in a Mouse Model of DMD
Neurology · AAN Annual Meeting 2022 · Etxaniz, Diaz, Bhardwaj, Olecya Tyaglo et al. · View paper →
AOC 1044: An Antibody Oligonucleotide Conjugate as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping
MDA Clinical & Scientific Conference · Etxaniz, Olecya Tyaglo et al. · View paper →
"If you're not living on the edge, you're taking up too much space."